Ciprinol - instructions for use, analogs, reviews and release forms (tablets 250 mg, 500 mg and 750 mg, injections of antibiotic in injections and infusions, CP) for the treatment of infections in adults, children and pregnancy. Composition and alcohol

In this article, you can read the instructions for using the drug Ciprinol. There are reviews of visitors to the site - consumers of this medication, as well as opinions of specialists on the use of antibiotic Cyprinol in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Ciprinol in the presence of existing structural analogues.Use for the treatment of infectious diseases in adults, children, as well as during pregnancy and lactation. Composition and interaction of the drug with alcohol.

Ciprinol - a broad-spectrum antimicrobial agent from the group of fluoroquinolones. It is bactericidal. Inhibits the DNA enzyme of the bacterial DNA, as a result of which DNA replication and the synthesis of bacterial cell proteins are disturbed. Ciprofloxacin acts both on multiplying microorganisms, and on microorganisms in a rest phase.

The drug is active against gram-negative bacteria: Escherichia coli (E. coli), Salmonella spp. (salmonella), Shigella spp. (shigella), Citrobacter spp., Klebsiella spp. (Klebsiella), Enterobacter spp., Proteus mirabilis, Proteus vulgaris, Serratia marcescens, Hafnia alvei, Edwardsiella tarda, Providencia spp., Morganella morganii, Vibrio spp., Yersinia spp., Haemophilus spp., Pseudomonas aeruginosa, Moraxella catarrhalis, Aeromonas spp ., Pasteurella multocida, Plesiomonas shigelloides, Campylobacter jejuni, Neisseria spp .; intracellular microorganisms: Legionella pneumophila (Legionella), Brucella spp, Chlamydia trachomatis (Chlamydia), Listeria monocytogenes, Mycobacterium tuberculosis (mycobacterium), Mycobacterium kansasii, Mycobacterium avium-intracellulare;. Gram-positive bacteria: Streptococcus spp. (Including Streptococcus pyogenes (Streptococcus), Streptococcus agalactiae), Staphylococcus spp. (Including Staphylococcus aureus (Staphylococcus aureus), Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saprophyticus). The majority of staphylococci, resistant to methicillin, are resistant to ciprofloxacin.

The drug is moderately sensitive to Streptococcus pneumoniae, Enterococcus faecalis.

To a drug resistant Corynebacterium spp., Bacteroides fragilis, Pseudomonas cepacia, Pseudomonas maltophila, Ureaplasma urealyticum (Ureaplasma), Clostridium difficile, Nocardia asteroides.

The effect of the drug on Treponema pallidum (treponema) has been studied insufficiently.

With Citrinol, there is no development of parallel resistance to other antibiotics not belonging to the group of inhibitors of gyrase, which makes it highly effective against bacteria that are resistant to aminoglycosides, penicillins, cephalosporins, tetracyclines.

Composition

Ciprofloxacin + excipients.

Pharmacokinetics

After taking the drug inside, Ciprinol is rapidly absorbed from the digestive tract. Eating slows down absorption, but does not affect bioavailability. Bioavailability varies from 50% to 85%. Ciprofloxacin is well distributed into tissues and body fluids, with high concentrations found in bile, lung, kidney, liver, gall bladder, uterus, semen, prostate tissue, tonsils, endometrium, fallopian tubes and ovaries. The concentration of ciprofloxacin in these tissues is higher than in serum. Ciprofloxacin also penetrates well into the liquid media of the eye, in the bones, bronchial secretions, saliva, skin, muscles, the pleura, the peritoneum and into the lymph. In the spinal fluid penetrates in a small amount, the concentration of ciprofloxacin in uninflated cerebral membranes is 6-10% of that in the blood serum, with the inflamed - 14-37%.The concentration of ciprofloxacin in neutrophils is 2-7 times higher than in serum. Penetrates through the placental barrier.

Biotransformed in the liver (15-30%) to form inactive metabolites (dietiltsiprofloksatsin, sulfotsiprofloksatsin, oksitsiprofloksatsin, formiltsiprofloksatsin). It is excreted mainly with urine (50-70%); 15-30% with feces.

Indications

Infectious-inflammatory diseases caused by microorganisms sensitive to the preparation, including:

• respiratory tract: pneumonia (except pneumococcal pneumonia), acute bronchitis and acute exacerbation of chronic bronchitis, bronchiectasis, cystic fibrosis (if the agent is gram-negative bacteria, especially Pseudomonas aeruginosa);
• ear, throat and nose (tonsillitis, tonsillitis, acute otitis media, sinusitis, mastoiditis);
• kidney and urinary tract (uncomplicated and complicated infections of the lower and upper urinary tract (urethritis, cystitis, pyelonephritis));
• pelvic and genital organs (epididymitis, prostatitis, salpingitis, endometritis, oophoritis, tubular abscess and pelvic inflammation, gonorrhea, chancroid, chlamydia);
• abdominal cavity (intraperitoneal abscess, cholecystitis, cholangitis (in combination with metronidazole, or clindamycin));
• infectious diarrhea (salmonellosis, campylobacteriosis, iersiniosis, shigellosis, cholera, typhoid fever, travelers' diarrhea, bacteriocarrier Salmonella typhi);
• skin and soft tissues (infected ulcers, infected wounds, abscesses, phlegmon, infections of the external auditory canal, infected burns);
• musculoskeletal system (osteomyelitis, septic arthritis);
• prevention and treatment of pulmonary form of anthrax;
• prevention and treatment of infections in patients with reduced immunity (against the background of immunosuppressant therapy).

Forms of release

Tablets coated with 250 mg, 500 mg and 750 mg.

Solution for infusion and concentrate for solution for infusion (injections in ampoules for injection).

Tablets of prolonged action, coated with a coating (Cyprinol SR).

Instructions for use and dosage

The dosage regimen is set individually, depending on the localization and severity of the infection, the state of the organism, age, body weight, the function of the patient's kidneys.

In uncomplicated diseases of the kidneys and urinary tract drug prescribed 250 mg twice a day, with complicated - 500-750 mg 2 times a day.

In diseases of the lower respiratory tract - 250 mg 2 times a day, in severe cases - 500-750 mg 2 times a day.

In the treatment of gonorrhea, the drug is administered once in a dose of 250-500 mg.

With enteritis, severe colitis, gynecological infections, prostatitis, osteomyelitis - 500-750 mg 2 times a day.

For the treatment of diarrhea - 250 mg 2 times a day.

For the prevention of surgical infections - 500-750 mg every other day.

The duration of treatment depends on the severity of the disease.

Tablets should be taken on an empty stomach, with plenty of fluids.

Possible intravenous administration of the drug. The dose of Cyprinol is determined depending on the severity of the disease, type of infection, body condition, age, body weight, kidney function of the patient.

The average recommended single dose is 200 mg (in severe infections - 400 mg), the frequency of administration is 2 times a day; the duration of treatment is 1-2 weeks, if necessary - longer.

The drug may be administered intravenously struino, but more preferably intravenous drip (in the form of a dropper) for 30 minutes (200 mg) and 60 minutes (400 mg).

In acute gonorrhea, 100 mg of the drug is administered once.

For the prevention of postoperative infections - 200 to 400 mg of Cyprinol are administered intravenously 30-60 minutes before the IV operation.

Tablets prolonged SR

Assign inside 1 time per day, after meals. Tablets should be swallowed whole, not liquid and squeezed with a sufficient amount of liquid.

The dose of Cyprinol CP depends on the severity of the disease, type of infection, body condition, age, body weight and kidney function.

Side effect

• nausea, vomiting;
• diarrhea;
• pseudomembranous colitis;
• flatulence;
• decreased appetite;
• Cholestatic jaundice (especially in patients with liver disease);
• hepatitis;
• increased activity of hepatic transaminases, alkaline phosphatase, LDH, bilirubin;
• headache;
• dizziness;
• increased fatigue;
• sense of anxiety;
• increased intracranial pressure;
• insomnia;
• nightmarish dreams;
• confusion of consciousness;
• depression;
• hallucination;
• fainting;
• migraine;
• thrombosis of the cerebral arteries;
• impairment of taste and smell;
• visual impairment (diplopia, change in color perception);
• noise in ears;
• hearing loss;
• tachycardia;
• heart rhythm disturbances;
• arterial hypotension;
• tides (with / in the introduction);
• eosinophilia, leukopenia, thrombocytopenia, neutropenia, anemia, thrombocytosis, hemolytic anemia;
• arthritis;
• tenosynovitis;
• rupture of tendons;
• arthralgia;
• myalgia;
• interstitial nephritis;
• glomerulonephritis;
• hematuria;
• retention of urine;
• itching;
• hives;
• angioedema;
• Stevens-Johnson syndrome;
• Lyell's syndrome;
• candidiasis;
• general weakness;
• photosensitization;
• increased sweating;
• phlebitis.

Contraindications

• pseudomembranous colitis (for intravenous administration);
• deficiency of glucose-6-phosphate dehydrogenase (for intravenous administration);
• pregnancy;
• lactation period (breastfeeding);
• children and adolescents under 18;
• increased sensitivity to ciprofloxacin or other drugs from the group of fluoroquinolones.

Application in pregnancy and lactation

Ciprinol is contraindicated in pregnancy and lactation (breastfeeding).

Application in elderly patients

With caution appoint the drug to elderly patients.

Use in children

Contraindicated in children and adolescents under the age of 18 years.

special instructions

When developing during or after ciprofloxacin treatment of severe and prolonged diarrhea, the diagnosis of pseudomembranous colitis should be excluded, which requires immediate discontinuation of the drug and the appointment of appropriate treatment.

If pain occurs in tendons or when the first signs of tendovaginitis appear, treatment should be discontinued due to the fact that individual cases of inflammation and even rupture of tendons during treatment with fluoroquinolones are described.

During the treatment period, in order to avoid the development of crystalluria, an increase in the recommended daily dose is unacceptable. Patients should receive a large amount of fluid to maintain normal diuresis and acid urine reaction.

Due to possible photosensitization during treatment with Ciprinol, avoid direct exposure to sunlight.

During treatment, patients should not consume alcohol.

Influence on the ability to drive vehicles and control mechanisms

When using the drug should refrain from engaging in potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

Drug Interactions

With the simultaneous use of ciprinol with didanosine, ciprofloxacin absorption decreases due to the formation of ciprofloxacin complexes with didanosine-containing magnesium and aluminum salts.

Due to a decrease in the activity of microsomal oxidation in hepatocytes, ciprofloxacin increases the concentration and increases the half-life of theophylline and other xanthines.

With the simultaneous use of ciprofloxacin and oral hypoglycemic drugs, indirect anticoagulants, a decrease in the prothrombin index is observed.

With the simultaneous use of ciprofloxacin and non-steroidal anti-inflammatory drugs (NSAIDs) (excluding acetylsalicylic acid), the risk of seizures increases.

Simultaneous reception of antacids, as well as preparations containing ions of aluminum, zinc, iron and magnesium, can cause a decrease in absorption of ciprofloxacin, so the interval between the appointment of these drugs should be at least 4 hours.

With the simultaneous use of ciprofloxacin and cyclosporine, the nephrotoxic effect of the latter is enhanced.

Metoclopramide accelerates the absorption of ciprofloxacin, which leads to a decrease in the time to reach its maximum concentration in the blood plasma.

Joint appointment of uricosuric drugs leads to a delay in excretion (up to 50%) and an increase in the plasma concentration of ciprofloxacin.

When combined with other antimicrobial agents (beta-lactam antibiotics, aminoglycosides, clindamycin, metronidazole), synergy is usually observed. Ciprinol can be used in combination with azlocillin and ceftazidime in infections caused by Pseudomonas spp .; with mezlocillin, azlocillin and other beta-lactam antibiotics - with streptococcal infections; with isoxazole penicillins and Vancomycin - with staphylococcal infections; with Metronidazole and Clindamycin - with anaerobic infections.

Analogues of the drug Ciprinol

Structural analogs for the active substance:

• Altsipro;
• Afenoxin;
• Basijen;
• Betaciprol;
• Zindolin;
• Isfipro;
• Quintor;
• Quipro;
• Liprokhin;
• Microfleks;
• Oftotsipro;
• PROCIPRO;
• Recipro;
• Siflox;
• Ceprova;
• Ciloxane;
• Cipraz;
• Cyprinol SR;
• Ciprobay;
• Ciprobide;
• Ciprobrin;
• Citrodox;
• Ciprolake;
• Tsiprolet;
• Ciprolone;
• Cipromed;
• Cipropane;
• Ciprosan;
• Ciprosine;
• Ciprosol;
• Ciprofloxabol;
• Ciprofloxacin;
• Cytar;
• Cifloxinal;
• Tsifran;
• Ecocylol.

Similar medicines:

Other medicines: